Full Text View
Tabular View
Study Results
Related Studies
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
This study has been completed.
Study NCT00294515   Information provided by Hoffmann-La Roche

First Received on February 21, 2006.   Last Updated on July 30, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cytomegalovirus Infections
More general conditions related to this trial
DNA Virus Infections
Herpesviridae Infections
Virus Diseases
Interventions listed in this trial
Valganciclovir
Additional drug interventions recognized in this trial
Ganciclovir
More general drug interventions related to this trial
Anti-Infective Agents
Antiviral Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Hoffmann-La Roche


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services